PolyOne Expands Healthcare Portfolio with Biomerics' Specialty Medical Solutions
CLEVELAND, June 2, 2014 /PRNewswire/ -- PolyOne Corporation (NYSE: POL), a premier global provider of specialized polymer materials, services and solutions, today announced that Biomerics has chosen PolyOne Distribution as the exclusive distributor for its Quadrathane™, Quadraflex™, and Quadraplast™ medical-grade thermoplastic polyurethanes in North America.
"Biomerics' Quadra biomaterials are an excellent complement to our healthcare portfolio. These highly biocompatible polymers will enhance our ability to help our customers accelerate speed-to-market, meet or exceed product performance requirements and navigate regulatory approvals more confidently," said Mark Crist, president, PolyOne Distribution.
Thermoplastic polyurethanes from Biomerics are used in a variety of medical device applications such as vascular access catheters, introducers, drainage catheters, interventional radiology devices, fluid management, coatings, balloons and wound care. They are available in a wide range of colors and offer a spectrum of performance characteristics.
"PolyOne is recognized globally for its commitment to the medical device market, dependable distribution, and customer service," said Travis Sessions, CEO of Biomerics. "Biomerics chose PolyOne Distribution to increase access of our materials and technology to the larger healthcare market. Given its strong market presence and specialty portfolio, PolyOne Distribution was a natural fit."
PolyOne Corporation, with 2013 revenues of $3.8 billion, is a premier provider of specialized polymer materials, services and solutions. The company is dedicated to serving customers in diverse industries around the globe, by creating value through collaboration, innovation and an unwavering commitment to excellence. Guided by its Core Values, Sustainability Promise and No Surprises PledgeSM, PolyOne is committed to its customers, employees, communities and shareholders through ethical, sustainable and fiscally responsible principles. For more information, visit www.polyone.com.
Biomerics, LLC is an innovative medical polymer solution provider to the medical device market. Biomerics specializes in biomedical materials, compounding, injection molding, extrusion, coating, and medical device fabrication. Biomerics manufactures its materials in ISO 13485 and FDA registered facilities in Salt Lake City, UT. More information is available at www.biomerics.com or contact us at 888-874-7787.
To access PolyOne's news library online, please go to www.polyone.com/news.
In this press release, statements that are not reported financial results or other historical information are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events and are not guarantees of future performance. They are based on management's expectations that involve a number of business risks and uncertainties, any of which could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. They use words such as "will," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial condition, performance and/or sales. Factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to: the final amount of charges resulting from the planned North American asset realignment and the Company's ability to realize anticipated savings and operational benefits from the asset realignment; our ability to achieve the strategic and other objectives relating to the acquisition of Spartech Corporation, including any expected synergies; our ability to successfully integrate Spartech and achieve the expected results of the acquisition, including, without limitation, the acquisition being accretive; disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; the financial condition of our customers, including the ability of customers (especially those that may be highly leveraged and those with inadequate liquidity) to maintain their credit availability; the speed and extent of an economic recovery, including the recovery of the housing market; our ability to achieve new business gains; the effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; changes in polymer consumption growth rates where we conduct business; changes in global industry capacity or in the rate at which anticipated changes in industry capacity come online; fluctuations in raw material prices, quality and supply and in energy prices and supply; production outages or material costs associated with scheduled or unscheduled maintenance programs; unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; an inability to achieve or delays in achieving or achievement of less than the anticipated financial benefit from initiatives related to working capital reductions, cost reductions and employee productivity goals; an inability to raise or sustain prices for products or services; an inability to maintain appropriate relations with unions and employees; the inability to achieve expected results from our acquisition activities; our ability to continue to pay cash dividends; the amount and timing of repurchases of our common shares, if any; and other factors affecting our business beyond our control, including, without limitation, changes in the general economy, changes in interest rates and changes in the rate of inflation. The above list of factors is not exhaustive.
We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. You are advised to consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and Exchange Commission.
SOURCE PolyOne Corporation